In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 767-771

  Fleck, Ralf ^a   Dietz, Annebärbel ^a   Hof, Herbert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Amphotericin B; Caspofungin; Fluconazole; Flucytosine; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE;

ANALYTIC METHOD; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DILUTION; DRUG CHOICE; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GERMANY; IN VITRO STUDY; INCUBATION TIME; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RELIABILITY; SPECIES DIFFERENCE; UNIVERSITY HOSPITAL; VALIDITY; COMPARATIVE STUDY; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; REPRODUCIBILITY;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; GERMANY; HOSPITALS, UNIVERSITY; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS;

EID: 34249995247     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl555     Document Type: Article

References (10)

1. Pfaller MA, Jones RN, Doem GV et al. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998; 36: 1886-9.
2. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359: 1135-44.
3. Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida knisel infection among patents with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-7.
4. Tortorano AM, Rigoni AL, Biraghi E et al. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: anfifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003; 52: 679-82.
5. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Second Edition: Approved Standard M27-A2. NCCLS, Wayne, PA, USA, 2002.
6. Barry AL, Pfaller MA, Brown SD et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 2000; 38: 3457-9.
7. Pfaller MA, Diekema DJ, Rex J et al. Correlation of MIC with outcome for Candida species tested against voriconazole: Analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-26.
8. Munoz P, Sanchez-Somolinos M, Alcala L et al. Candida krusei fungaemia: Antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 2005; 55: 188-93.
9. Wanger A, Mills K, Nelson P et al. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520-2.
10. Park BJ, Arthington-Skaggs BA, Hajjeh RA et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006; 50: 1287-92.